Evidence map›Paper›PMID 39322240›Full record

ArticleFunction (Oxford, England)2024

The P2Y6 Receptor as a Potential Keystone in Essential Hypertension.

Nuria Daghbouche-Rubio, Inés Álvarez-Miguel, Victor Alejandro Flores, Jorge Rojo-Mencía, Manuel Navedo, Madeleine Nieves-Citrón, Pilar Cidad, M Teresa Pérez-García, José R López-López

Abstract read
In one paragraph

Article in Function (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nuria Daghbouche-RubioDepartamento de Bioquímica y Biología Molecular y Fisiología e Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y Consejo Superior de Investigaciones Científicas (CSIC), Valladolid, 47003, Spain.ORCID 0000-0002-6768-3999
Inés Álvarez-MiguelDepartamento de Bioquímica y Biología Molecular y Fisiología e Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y Consejo Superior de Investigaciones Científicas (CSIC), Valladolid, 47003, Spain.ORCID 0000-0001-5054-2172
Victor Alejandro FloresDepartment of Pharmacology, University of California Davis, Davis, CA 95616, USA.
Jorge Rojo-MencíaDepartamento de Bioquímica y Biología Molecular y Fisiología e Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y Consejo Superior de Investigaciones Científicas (CSIC), Valladolid, 47003, Spain.ORCID 0009-0004-8603-219X
Manuel NavedoDepartment of Pharmacology, University of California Davis, Davis, CA 95616, USA.ORCID 0000-0001-6864-6594
Madeleine Nieves-CitrónDepartment of Pharmacology, University of California Davis, Davis, CA 95616, USA.ORCID 0000-0003-1935-8400
Pilar CidadDepartamento de Bioquímica y Biología Molecular y Fisiología e Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y Consejo Superior de Investigaciones Científicas (CSIC), Valladolid, 47003, Spain.ORCID 0000-0002-6338-7738
M Teresa Pérez-GarcíaDepartamento de Bioquímica y Biología Molecular y Fisiología e Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y Consejo Superior de Investigaciones Científicas (CSIC), Valladolid, 47003, Spain.ORCID 0000-0001-8540-8117
José R López-LópezDepartamento de Bioquímica y Biología Molecular y Fisiología e Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y Consejo Superior de Investigaciones Científicas (CSIC), Valladolid, 47003, Spain.ORCID 0000-0002-3870-421X

Funding

Coupling of Vascular Cav1.2 Channels In Health & DiseaseR01HL121059 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NAVEDO, MANUEL F · 2015 to 2024
$4.5M
Cerebral Vascular Smooth Muscle Dysfunction in Alzheimer's DiseaseR01HL149127 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NAVEDO, MANUEL F · 2019 to 2022
$2.7M
NHLBI NIH HHS R01 HL121059NHLBI NIH HHS R01 HL149127NIH HHS R01HL121059
6 · The paper itself

Abstract

Essential hypertension (HT) is a highly prevalent cardiovascular disease of unclear physiopathology. Pharmacological studies suggest that purinergic P2Y6 receptors (P2ry6) play important roles in cardiovascular function and may contribute to angiotensin II (AgtII) pathophysiological effects. Here, we tested the hypothesis that functional coupling between P2ry6 and AgtII receptors mediates altered vascular reactivity in HT. For this, a multipronged approach was implemented using mesenteric vascular smooth muscle cells (VSMCs) and arteries from Blood Pressure Normal (BPN) and Blood Pressure High (BPH) mice. Differential transcriptome profiling of mesenteric artery VSMCs identified P2ry6 purinergic receptor mRNA as one of the top upregulated transcripts in BPH. P2Y receptor activation elicited distinct vascular responses in mesenteric arteries from BPN and BPH mice. Accordingly, 10 µm UTP produced a contraction close to half-maximal activation in BPH arteries but no response in BPN vessels. AgtII-induced contraction was also higher in BPH mice despite having lower AgtII receptor type-1 (Agtr1) expression and was sensitive to P2ry6 modulators. Proximity ligation assay and super-resolution microscopy showed closer localization of Agtr1 and P2ry6 at/near the membrane of BPH mice. This proximal association was reduced in BPN mice, suggesting a functional role for Agtr1-P2ry6 complexes in the hypertensive phenotype. Intriguingly, BPN mice were resistant to AgtII-induced HT and showed reduced P2ry6 expression in VSMCs. Altogether, results suggest that increased functional coupling between P2ry6 and Agtr1 may contribute to enhanced vascular reactivity during HT. In this regard, blocking P2ry6 could be a potential pharmacological strategy to treat HT.

Indexed as

Essential HypertensionMuscle, Smooth, VascularReceptors, Purinergic P2Angiotensin IIAnimalsBlood PressureMaleMesenteric ArteriesMiceMice, Inbred C57BLMyocytes, Smooth MuscleAngiotensin IIpurinoceptor P2Y6Receptors, Purinergic P2blood pressureessential hypertensionG-protein coupled receptorspurinergic systemsignal transductionsmooth musclevessel myography

Identifiers

PMID39322240
PMCPMC11577605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.